224 related articles for article (PubMed ID: 33069067)
1. Rational design of cell-permeable cyclic peptides containing a d-Pro-l-Pro motif.
Wen J; Liao H; Stachowski K; Hempfling JP; Qian Z; Yuan C; Foster MP; Pei D
Bioorg Med Chem; 2020 Oct; 28(20):115711. PubMed ID: 33069067
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives.
Song YL; Peach ML; Roller PP; Qiu S; Wang S; Long YQ
J Med Chem; 2006 Mar; 49(5):1585-96. PubMed ID: 16509576
[TBL] [Abstract][Full Text] [Related]
3. Global optimization of conformational constraint on non-phosphorylated cyclic peptide antagonists of the Grb2-SH2 domain.
Long YQ; Lung FD; Roller PP
Bioorg Med Chem; 2003 Sep; 11(18):3929-36. PubMed ID: 12927853
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for a non-phosphorus-containing cyclic peptide binding to Grb2-SH2 domain with high affinity.
Li P; Zhang M; Peach ML; Zhang X; Liu H; Nicklaus M; Yang D; Roller PP
Biochem Biophys Res Commun; 2003 Aug; 307(4):1038-44. PubMed ID: 12878216
[TBL] [Abstract][Full Text] [Related]
5. Discovery of thioether-bridged cyclic pentapeptides binding to Grb2-SH2 domain with high affinity.
Jiang S; Liao C; Bindu L; Yin B; Worthy KW; Fisher RJ; Burke TR; Nicklaus MC; Roller PP
Bioorg Med Chem Lett; 2009 May; 19(10):2693-8. PubMed ID: 19362470
[TBL] [Abstract][Full Text] [Related]
6. Cyclic peptidyl inhibitors of Grb2 and tensin SH2 domains identified from combinatorial libraries.
Zhang Y; Zhou S; Wavreille AS; DeWille J; Pei D
J Comb Chem; 2008; 10(2):247-55. PubMed ID: 18257540
[TBL] [Abstract][Full Text] [Related]
7. Designing Cell-Permeable Macrocyclic Peptides.
Appiah Kubi G; Dougherty PG; Pei D
Methods Mol Biol; 2019; 2001():41-59. PubMed ID: 31134566
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structural characterization of a monocarboxylic inhibitor for GRB2 SH2 domain.
Xiao T; Sun L; Zhang M; Li Z; Haura EB; Schonbrunn E; Ji H
Bioorg Med Chem Lett; 2021 Nov; 51():128354. PubMed ID: 34506932
[TBL] [Abstract][Full Text] [Related]
9. Binding affinity difference induced by the stereochemistry of the sulfoxide bridge of the cyclic peptide inhibitors of Grb2-SH2 domain: NMR studies for the structural origin.
Shi YH; Song YL; Lin DH; Tan J; Roller PP; Li Q; Long YQ; Song GQ
Biochem Biophys Res Commun; 2005 May; 330(4):1254-61. PubMed ID: 15823578
[TBL] [Abstract][Full Text] [Related]
10. Utilization of 3'-carboxy-containing tyrosine derivatives as a new class of phosphotyrosyl mimetics in the preparation of novel non-phosphorylated cyclic peptide inhibitors of the Grb2-SH2 domain.
Song YL; Tan J; Luo XM; Long YQ
Org Biomol Chem; 2006 Feb; 4(4):659-66. PubMed ID: 16467940
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and utilization of chiral alpha-methylated alpha-amino acids with a carboxyalkyl side chain in the design of novel Grb2-SH2 peptide inhibitors free of phosphotyrosine.
Long YQ; Xue T; Song YL; Liu ZL; Huang SX; Yu Q
J Med Chem; 2008 Oct; 51(20):6371-80. PubMed ID: 18821748
[TBL] [Abstract][Full Text] [Related]
12. Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides.
Lee K; Zhang M; Liu H; Yang D; Burke TR
J Med Chem; 2003 Jun; 46(13):2621-30. PubMed ID: 12801226
[TBL] [Abstract][Full Text] [Related]
13. Solution structure of the Grb2 SH2 domain complexed with a high-affinity inhibitor.
Ogura K; Shiga T; Yokochi M; Yuzawa S; Burke TR; Inagaki F
J Biomol NMR; 2008 Nov; 42(3):197-207. PubMed ID: 18830565
[TBL] [Abstract][Full Text] [Related]
14. Functional preference of the constituent amino acid residues in a phage-library-based nonphosphorylated inhibitor of the Grb2-SH2 domain.
Lung FD; Long YQ; Roller PP; King CR; Varady J; Wu XW; Wang S
J Pept Res; 2001 Jun; 57(6):447-54. PubMed ID: 11437948
[TBL] [Abstract][Full Text] [Related]
15. Peptide bicycles that inhibit the Grb2 SH2 domain.
Quartararo JS; Wu P; Kritzer JA
Chembiochem; 2012 Jul; 13(10):1490-6. PubMed ID: 22689355
[TBL] [Abstract][Full Text] [Related]
16. Effects of peptidic antagonists of Grb2-SH2 on human breast cancer cells.
Chen CH; Chen MK; Jeng KC; Lung FD
Protein Pept Lett; 2010 Jan; 17(1):44-53. PubMed ID: 19508206
[TBL] [Abstract][Full Text] [Related]
17. A conformationally fixed analog of the peptide mimic Grb2-SH2 domain: synthesis and evaluation against the A431 cancer cell.
Iwata T; Tanaka K; Tahara T; Nozaki S; Onoe H; Watanabe Y; Fukase K
Mol Biosyst; 2013 May; 9(5):1019-25. PubMed ID: 23403766
[TBL] [Abstract][Full Text] [Related]
18. Cell-permeable bicyclic peptide inhibitors against intracellular proteins.
Lian W; Jiang B; Qian Z; Pei D
J Am Chem Soc; 2014 Jul; 136(28):9830-3. PubMed ID: 24972263
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics.
Jiang S; Li P; Peach ML; Bindu L; Worthy KW; Fisher RJ; Burke TR; Nicklaus M; Roller PP
Biochem Biophys Res Commun; 2006 Oct; 349(2):497-503. PubMed ID: 16945340
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a Direct Ras Inhibitor by Screening a Combinatorial Library of Cell-Permeable Bicyclic Peptides.
Trinh TB; Upadhyaya P; Qian Z; Pei D
ACS Comb Sci; 2016 Jan; 18(1):75-85. PubMed ID: 26645887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
